Key Points
- CEO Thomas Hogan sold 139,713 Cellebrite shares for approximately $2.15 million at an average price of $15.39, reducing his holdings by 15.02% to 790,548 shares.
- Cellebrite shares were down 29.2%, opening at $10.80, compared with a 12-month range of $9.58 to $19.98.
- The company reported quarterly EPS of $0.11, above the $0.05 consensus estimate, while revenue of $131.14 million slightly missed forecasts. Analysts maintain a consensus “Moderate Buy” rating with a $21.80 target price.
Cellebrite DI Ltd. (NASDAQ:CLBT - Get Free Report) CEO Thomas Hogan sold 139,713 shares of the business's stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $15.39, for a total value of $2,150,183.07. Following the completion of the sale, the chief executive officer owned 790,548 shares in the company, valued at $12,166,533.72. The trade was a 15.02% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.
Cellebrite DI Stock Down 29.2%
Shares of CLBT opened at $10.80 on Friday. Cellebrite DI Ltd. has a twelve month low of $9.58 and a twelve month high of $19.98. The company has a 50 day moving average of $14.52 and a 200-day moving average of $14.05. The stock has a market capitalization of $2.69 billion, a P/E ratio of 38.57, a P/E/G ratio of 1.89 and a beta of 1.18.
Cellebrite DI (NASDAQ:CLBT - Get Free Report) last issued its quarterly earnings results on Thursday, August 13th. The company reported $0.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.05 by $0.06. Cellebrite DI had a net margin of 14.48% and a return on equity of 18.38%. The firm had revenue of $131.14 million for the quarter, compared to analyst estimates of $131.87 million. On average, sell-side analysts anticipate that Cellebrite DI Ltd. will post 0.41 earnings per share for the current fiscal year.
Institutional Trading of Cellebrite DI
Several institutional investors and hedge funds have recently bought and sold shares of the business. Towarzystwo Funduszy Inwestycyjnych PZU SA boosted its stake in shares of Cellebrite DI by 81.0% during the 4th quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA now owns 1,900 shares of the company's stock worth $34,000 after acquiring an additional 850 shares during the period. Advisory Services Network LLC acquired a new position in shares of Cellebrite DI during the 3rd quarter worth approximately $40,000. CWM LLC raised its stake in Cellebrite DI by 57.0% in the 4th quarter. CWM LLC now owns 2,449 shares of the company's stock valued at $44,000 after acquiring an additional 889 shares during the period. Elevation Wealth Partners LLC bought a new stake in Cellebrite DI in the 2nd quarter valued at $44,000. Finally, First Horizon Corp lifted its holdings in Cellebrite DI by 421.8% during the 4th quarter. First Horizon Corp now owns 2,891 shares of the company's stock valued at $52,000 after purchasing an additional 2,337 shares during the last quarter. Institutional investors own 45.88% of the company's stock.
Wall Street Analyst Weigh In
CLBT has been the topic of several analyst reports. Needham & Company LLC dropped their target price on Cellebrite DI from $18.00 to $15.00 and set a "buy" rating on the stock in a report on Friday, May 15th. Weiss Ratings upgraded Cellebrite DI from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Monday, May 18th. Finally, DA Davidson boosted their price target on Cellebrite DI from $20.00 to $22.00 and gave the stock a "buy" rating in a research report on Thursday, August 6th. Five research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $21.80.
Check Out Our Latest Stock Report on Cellebrite DI
More Cellebrite DI News
Here are the key news stories impacting Cellebrite DI this week:
- Positive Sentiment: Cellebrite reported second-quarter adjusted EPS of $0.11, above the $0.05 consensus estimate cited by MarketBeat, while subscription revenue continued to rise. Management also raised its adjusted EBITDA target. Cellebrite second-quarter earnings report
- Positive Sentiment: D.A. Davidson maintained its Buy rating, and one analyst argued that the selloff may be excessive relative to Cellebrite’s longer-term growth opportunity. D.A. Davidson rating
- Positive Sentiment: Unusual options activity included nearly 20,000 call contracts, substantially above average volume, suggesting some traders were positioning for a rebound, although this is speculative rather than a fundamental catalyst.
- Neutral Sentiment: Cellebrite announced a planned CEO succession, with Shiven Ramji replacing Thomas E. Hogan effective August 13. The transition could bring a new strategic direction, but investors may initially view leadership change as an uncertainty. Cellebrite CEO succession announcement
- Negative Sentiment: The main pressure came from lowered guidance: third-quarter revenue was projected at $145 million-$148 million versus a $150.3 million consensus, while full-year revenue guidance of $555 million-$561 million fell short of the $568.1 million estimate. The company also lowered its full-year ARR outlook, indicating weaker near-term growth than previously expected. Cellebrite 2026 outlook announcement
- Negative Sentiment: Quarterly revenue of $131.14 million slightly missed the $131.87 million estimate, and another earnings estimate placed EPS at $0.11 versus $0.12 expected. The combination of an ARR miss and weaker outlook outweighed the reported EPS beat. Cellebrite investigation notice
- Negative Sentiment: Several law firms announced investigations into possible securities-law violations and the accuracy of Cellebrite’s prior projections and disclosures. These are allegations, not findings, but they add legal and reputational risk after the selloff. Kaplan Fox investigation notice
- Negative Sentiment: CEO Thomas Hogan sold 139,713 shares worth approximately $2.15 million, a 15% reduction in his position. Although the sale may be related to the leadership transition or personal financial planning, its timing can weigh on sentiment. SEC insider trading filing
Cellebrite DI Company Profile
(
Get Free Report)
Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company's technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.
The company's flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
